JP2024539385A - Ａｋｒ１ｃ３活性化ｄｎａアルキル化剤、およびその医学的応用 - Google Patents
Ａｋｒ１ｃ３活性化ｄｎａアルキル化剤、およびその医学的応用 Download PDFInfo
- Publication number
- JP2024539385A JP2024539385A JP2024526649A JP2024526649A JP2024539385A JP 2024539385 A JP2024539385 A JP 2024539385A JP 2024526649 A JP2024526649 A JP 2024526649A JP 2024526649 A JP2024526649 A JP 2024526649A JP 2024539385 A JP2024539385 A JP 2024539385A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- tumor
- compounds
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07C201/06—Preparation of nitro compounds
- C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
- C07C205/38—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. nitrodiphenyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/564—Three-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2021/129077 WO2023077452A1 (zh) | 2021-11-05 | 2021-11-05 | Akr1c3活化的dna烷化剂及其医药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024539385A true JP2024539385A (ja) | 2024-10-28 |
| JP2024539385A5 JP2024539385A5 (https=) | 2024-11-13 |
Family
ID=86240506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526649A Pending JP2024539385A (ja) | 2021-11-05 | 2021-11-05 | Ａｋｒ１ｃ３活性化ｄｎａアルキル化剤、およびその医学的応用 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4428138A4 (https=) |
| JP (1) | JP2024539385A (https=) |
| KR (1) | KR20240110013A (https=) |
| CN (1) | CN118201940A (https=) |
| TW (1) | TW202320804A (https=) |
| WO (1) | WO2023077452A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114106042B (zh) * | 2021-11-12 | 2022-09-16 | 深圳艾欣达伟医药科技有限公司 | 一种氘代化合物及其制备方法和应用 |
| KR20260009356A (ko) | 2023-05-11 | 2026-01-19 | 아센타위츠 파마슈티컬즈 리미티드 | 주사액 제제 및 이의 제조 방법, 및 상용성 약액 및 이의 제조 방법 |
| WO2025140580A1 (zh) * | 2023-12-28 | 2025-07-03 | 深圳艾欣达伟医药科技有限公司 | 化合物晶型 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018513876A (ja) * | 2015-03-10 | 2018-05-31 | アセンタ ファーマシューティカルズ リミテッド | Ｄｎａアルキル化剤 |
| JP2018517710A (ja) * | 2015-11-16 | 2018-07-05 | アセンタ ファーマシューティカルズ リミテッド | （ｒ）−および（ｓ）−１−（３−（３−ｎ，ｎ−ジメチルアミノカルボニル）フェノキシル−４−ニトロフェニル）−１−エチル−ｎ，ｎ’−ビス（エチレン）ホスホルアミデート、組成物ならびにその使用方法および製造方法 |
| WO2020228685A1 (zh) * | 2019-05-13 | 2020-11-19 | 深圳艾欣达伟医药科技有限公司 | 含氟化合物及抗癌医药用途 |
| WO2021083310A1 (zh) * | 2019-11-01 | 2021-05-06 | 深圳艾欣达伟医药科技有限公司 | 作为非pgp底物的抗癌化合物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016161342A2 (en) * | 2015-04-02 | 2016-10-06 | Threshold Pharmaceuticals, Inc. | Nitrobenzyl derivatives of anti-cancer agents |
| TWI837402B (zh) * | 2019-12-20 | 2024-04-01 | 大陸商深圳艾欣達偉醫藥科技有限公司 | 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途 |
-
2021
- 2021-11-05 EP EP21962965.6A patent/EP4428138A4/en active Pending
- 2021-11-05 CN CN202180103860.6A patent/CN118201940A/zh active Pending
- 2021-11-05 JP JP2024526649A patent/JP2024539385A/ja active Pending
- 2021-11-05 KR KR1020247018893A patent/KR20240110013A/ko active Pending
- 2021-11-05 WO PCT/CN2021/129077 patent/WO2023077452A1/zh not_active Ceased
-
2022
- 2022-11-04 TW TW111142123A patent/TW202320804A/zh unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018513876A (ja) * | 2015-03-10 | 2018-05-31 | アセンタ ファーマシューティカルズ リミテッド | Ｄｎａアルキル化剤 |
| JP2018517710A (ja) * | 2015-11-16 | 2018-07-05 | アセンタ ファーマシューティカルズ リミテッド | （ｒ）−および（ｓ）−１−（３−（３−ｎ，ｎ−ジメチルアミノカルボニル）フェノキシル−４−ニトロフェニル）−１−エチル−ｎ，ｎ’−ビス（エチレン）ホスホルアミデート、組成物ならびにその使用方法および製造方法 |
| WO2020228685A1 (zh) * | 2019-05-13 | 2020-11-19 | 深圳艾欣达伟医药科技有限公司 | 含氟化合物及抗癌医药用途 |
| JP2022533346A (ja) * | 2019-05-13 | 2022-07-22 | アセンタウィッツ ファーマシューティカルズ リミテッド | フッ素含有化合物およびその抗癌医学的使用 |
| WO2021083310A1 (zh) * | 2019-11-01 | 2021-05-06 | 深圳艾欣达伟医药科技有限公司 | 作为非pgp底物的抗癌化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202320804A (zh) | 2023-06-01 |
| CN118201940A (zh) | 2024-06-14 |
| EP4428138A1 (en) | 2024-09-11 |
| WO2023077452A1 (zh) | 2023-05-11 |
| EP4428138A4 (en) | 2025-08-27 |
| KR20240110013A (ko) | 2024-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230339991A1 (en) | Hypoxia-activated dna alkylating agent and medical use thereof | |
| JP2024539385A (ja) | Ａｋｒ１ｃ３活性化ｄｎａアルキル化剤、およびその医学的応用 | |
| AU2016357728B2 (en) | (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation | |
| JP2026053650A (ja) | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 | |
| PH12015502091B1 (en) | Cdc7 inhibitors | |
| US20120040995A1 (en) | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs | |
| JP2009538317A (ja) | 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ | |
| Banerjee et al. | X-ray crystallography-guided design, antitumor efficacy, and QSAR analysis of metabolically stable cyclopenta-pyrimidinyl dihydroquinoxalinone as a potent tubulin polymerization inhibitor | |
| Weng et al. | Design, synthesis, and anticancer evaluation of long-chain alkoxylated mono-carbonyl analogues of curcumin | |
| Braconi et al. | New dual P-glycoprotein (P-gp) and human carbonic anhydrase XII (hCA XII) inhibitors as multidrug resistance (MDR) reversers in cancer cells | |
| EA027987B1 (ru) | Оксазолидин-2-онпиримидиновые производные | |
| US20210253603A1 (en) | Main group metal complex and its preparation method and use | |
| TW200811185A (en) | Fused pyrimidones and thiopyrimidones, and uses thereof | |
| Lu et al. | Synthesis and preliminary evaluation of 18F-icotinib for EGFR-targeted PET imaging of lung cancer | |
| CN112533610B (zh) | 用于治疗腺样囊性癌的包含双氟烷基-1,4-苯并二氮杂䓬酮化合物的组合物 | |
| Xu et al. | A self-activating nanoized vascular disrupting agent for selective anti-tumor therapy | |
| Shan et al. | First total synthesis, antitumor evaluation and target identification of mornaphthoate E: a new tubulin inhibitor template acting on PI3K/Akt signaling pathway | |
| JP2024001205A (ja) | エラクリダールの重水素化類似体 | |
| US20220168431A1 (en) | Methods of treating cancer using trimetazidine-based compounds | |
| JP2009521484A (ja) | ３−アリール置換キナゾロンおよびその使用 | |
| US20240016784A1 (en) | Y box binding protein 1 inhibitors | |
| CN101898979B (zh) | 含二苯乙烯片段的苯基硝酮类化合物及其用途 | |
| TW202523322A (zh) | 吉西他濱抗癌衍生物及其抗癌醫藥用途和製備方法 | |
| Peng et al. | Novel N-phenyl-2-(aniline) benzamide hydrochloride salt development for colon cancer therapy | |
| JP7646243B2 (ja) | 医薬組成物の肺癌治療における使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241105 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241105 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250814 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250819 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251118 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260303 |